Clinical Trial Update: Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating switching from DAPT to dual pathway inhibition with low-dose rivaroxaban in addition to aspirin for patients with cor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED | Results posted: 2023-04-26